MPL and essential thrombocythemia: How TPO-R interacts with JAK2 is particularly relevant in the context of disease driven by mutations in JAK2, specifically JAK2 V617F, which occurs in about half of patients with ET and MF, and most patients with polycythemia vera (34, 74–77).